Onco-hematologia

Estudo randomizado | Tomografia computadorizada vs. [18F]FDG-PET-TC para febre neutropênica persistente ou recorrente em pacientes de alto risco.

5 Jul, 2022 | 11:37h

[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link para o resumo – $ para o texto completo)

Comentário no Twitter

NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck

— The Lancet Haematology (@TheLancetHaem) June 29, 2022

FDA alerta sobre possível risco aumentado de morte e de sérios efeitos adversos com uso de duvelisibe.

5 Jul, 2022 | 11:21h

FDA Warns About Possible Increased Risk of Death and Serious Side Effects With Duvelisib – The ASCO Post

Editorial | Impacto das células tumorais circulantes como componentes do estadiamento do mieloma múltiplo.

5 Jul, 2022 | 11:19h

Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time? – Journal of Clinical Oncology

Estudos originais:

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma – Journal of Clinical Oncology

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma – Journal of Clinical Oncology

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile – Journal of Clinical Oncology

Diretrizes 2022 para o tratamento e a profilaxia do tromboembolismo venoso em pacientes com câncer, incluindo aqueles com COVID-19.

4 Jul, 2022 | 12:24h

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19 – The Lancet Oncology

Conteúdos relacionados:

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy – Cochrane Library

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer – Blood Advances

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology – Journal of the National Comprehensive Cancer Network

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review

Estudo randomizado | Lisocabtagene maraleucel vs. cuidado padrão com quimioterapia de resgate seguida de transplante autólogo de células-tronco como segunda linha de tratamento em pacientes com linfoma B de células grandes recidivante ou refratário.

22 Jun, 2022 | 21:22h

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Estudo de braço único fase 2 | Antivirais de ação direta como tratamento primário de linfomas não Hodgkin indolentes associados ao vírus da hepatite C.

21 Jun, 2022 | 12:32h

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi – Journal of Clinical Oncology

Desfechos de 10 anos de estudo randomizado | Momento da cura para crianças e jovens adultos com leucemia linfoblástica aguda (LLA) independe de fatores de risco iniciais.

21 Jun, 2022 | 12:31h

Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)

Diretriz de recomendação | Diagnóstico e tratamento da mastocitose sistêmica.

19 Jun, 2022 | 14:16h

Diagnosis and treatment of systemic mastocytosis in Brazil: Recommendations of a multidisciplinary expert panel – Hematology, Transfusion and Cell Therapy

Sistema de escore para prognóstico molecular nas síndromes mielodisplásicas.

19 Jun, 2022 | 13:56h

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes – NEJM Evidence

Seguimento de 2 anos de estudo de braço único | Ciltacabtageno Autoleucel, uma terapia de células T do receptor de antígeno quimérico anticélula B de maturação, para mieloma múltiplo recorrente/refratário.

19 Jun, 2022 | 13:02h

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up – Journal of Clinical Oncology

Estudo original: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study – The Lancet (link para o resumo – $ para o texto completo)